pegozafermin

From Aaushi

Jump to navigation Jump to search

^[1]

Indications

treatment of nonalcoholic steatohepatitis (NASH)

Dosage

15 mg or 30 mg SC weekly
44 mg SC every other week

Adverse effects

diarrhea, nausea

Mechanism of action

fibroblast growth factor 21 (FGF21) analogue
- FGF21 has favorable metabolic effects in the liver

More general terms

gastrointestinal agent

References

↑ Loomba R et al. Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH. N Engl J Med 2023 Sep 14; 389:998. PMID: https://www.ncbi.nlm.nih.gov/pubmed/37356033 PMCID: PMC10718287 (available on 2024-03-14) https://www.nejm.org/doi/10.1056/NEJMoa2304286

Retrieved from "https://aaushi.info/w/index.php?title=A492084&oldid=1192101"

↑ Back to top